HPE HPE 90 – November 2018 | Page 5
editorial
The closer the UK gets to leaving
the EU, the more questions that
remain unanswered
It has been over two years since 52% of UK voters decided that the country
was better off leaving the European Union than staying in. Despite this, it
sometimes feels as though no one is any closer to providing answers as to what
Brexit will actually look like in practice than they were back then.
Among the many pressing issues to thrash out, such as how the Northern
Irish border with the Republic is likely to be affected, it is of great concern that
Brexit cold severely disrupt the passage of medicines between Britain and the
EU. Whether you love or loathe the idea of Brexit, it is alarming how little solid
information there is on how stock levels, the medicines supply chain and, by
extension, patient care will be affected after Britain exits the EU in March 2019.
Naturally, concerns over patients’ access to vital medicines post-Brexit
have dominated headlines in the British press of late. For example, the UK’s
politicians have urged the Government to maintain medicines supplies after
March (see page 7 for more), but it is still unclear as to what can feasibly be done
to guarantee this – especially in light of global medicines shortages.
While it is welcome that politicans are at least discussing solutions to this
potential problem, details are still very thin on the ground. With so little time
left until Brexit comes into effect, it is incredibly important that talk turns into
action and a firm plan is put in place to minimise disruption and maximise
safety for pharmacists and patients alike.
In September, the Department of Health and Social Care revealed that
if Britain crashes out of the EU without a deal, then all the hard work that
has already gone into preparing for the Falsified Medicines Directive (FMD )
implementation deadline in February may have to be reversed (see page 6 for
more). This is likely to have many UK pharmacists wringing their hands. The
prospect of all of that hard work preparing for FMD being wasted is certainly
difficult to swallow. There is even less information on how this scenario could
affect the rest of Europe.
For pharmacists to be able to offer the best – and safest – possible care to
their patients, they need full and frank answers to quaestions on these pressing
issues. So my challenge to both EU leaders and the British Government is this;
stop the petty political point-scoring on both sides and start giving practical
solutions to these obstacles. Patient care across Europe depends on it.
Practical solutions must
replace petty political point
scoring on both sides
Beth Kennedy Editor-in-chief
Editorial Advisory Board
Tiene Bauters
PhD PharmD Belgium
Bruce Burnett
MRPharmS MMedSci UK
Group Editor
Gemma Collins Anna Carollo
PharmD PhD MS Italy
Editor-in-chief
Beth Kennedy Mikael Daouphars
PharmD PhD France
Editor, Secondary Care
Andrea Porter Olga Delgado Sanchez
PharmD Spain
Art Editor
James Depree Oweikumo Eradiri
PhD FRSPH FFRPS UK
Sales enquiries
Greg Damalis
T +44 (0)20 7214 0611
E [email protected] David Hellens
MPharm PgDip IPresc UK
Martin J Hug
PhD Germany
Nadia Naous
MPharm UK
Michael Scott
BSc PhD FPSNI UK
María José Tamés
PhD Spain
Marta Trojniak
PharmD MPH Italy
Subscription enquiries
Bianca Pettifor
T +44 (0)20 7214 0534
E [email protected]
Subscription rates
UK Personal subscriptions £75,
Institutions £150; Outside UK
€160 (personal subscriptions) or
€275 (institutions); Back issues/
single copies (each) £30 (€50)
Copyright © Cogora Limited
2018. The contents of this
publication are protected by
copyright. All rights reserved.
No part of this publication may
be produced, stored in a retrieval
system or transmitted in any
form or by any means without
the written permission of the
publisher. The views expressed
in this publication are not
necessarily those of the publisher
or editorial advisors. While the
publisher and editorial advisors
have taken every care with
regard to accuracy of editorial
and advertisement contributions,
they cannot be held responsible
for any errors or omissions
contained therein.
Published in the United Kingdom
by Cogora Limited, 140 London
Wall, London EC2Y 5DN, UK.
T +44 (0)20 7214 0500
F +44 (0)20 7214 0501
E [email protected]
W cogora.com
hospitalpharmacyeurope.com | 2018 | Issue 90 | 5